title: A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition.
abstract: Proteasome inhibitors are emerging as a new class of chemopreventive agents and have gained huge importance as potential pharmacological tools in breast cancer treatment. Improved understanding of the role played by proteases and their specific inhibitors in humans offers novel and challenging opportunities for preventive and therapeutic intervention. In this study, we demonstrated that the Bowman-Birk protease inhibitor from Vigna unguiculata seeds, named black-eyed pea trypsin/chymotrypsin Inhibitor (BTCI), potently suppresses human breast adenocarcinoma cell viability by inhibiting the activity of proteasome 20S. BTCI induced a negative growth effect against a panel of breast cancer cells, with a concomitant cytostatic effect at the G2/M phase of the cell cycle and an increase in apoptosis, as observed by an augmented number of cells at the sub-G1 phase and annexin V-fluorescin isothiocyanate (FITC)/propidium iodide (PI) staining. In contrast, BTCI exhibited no cytotoxic effect on normal mammary epithelial cells. Moreover, the increased levels of intracellular reactive oxygen species (ROS) and changes in the mitochondrial membrane potential in cells treated with BTCI indicated mitochondrial damage as a crucial cellular event responsible for the apoptotic process. The higher activity of caspase in tumoral cells treated with BTCI in comparison with untreated cells suggests that BTCI induces apoptosis in a caspase-dependent manner. BTCI affected NF-kB target gene expression in both non invasive and invasive breast cancer cell lines, with the effect highly pronounced in the invasive cells. An increased expression of interleukin-8 (IL-8) in both cell lines was also observed. Taken together, these results suggest that BTCI promotes apoptosis through ROS-induced mitochondrial damage following proteasome inhibition. These findings highlight the pharmacological potential and benefit of BTCI in breast cancer treatment.
authors.affiliation: Laboratory of Molecular Biophysics, Institute of Biological Sciences, University of Brasilia , Brasilia, Brazil.
authors.forename: A
authors.initials: A
authors.lastname: Mehdad
authors.affiliation: Faculty of Medicine, Department of Molecular Pathology, University of Brasilia , Brasilia, Brazil.
authors.forename: Giselle
authors.initials: G
authors.lastname: Xavier Reis
authors.affiliation: Laboratory of Molecular Biophysics, Institute of Biological Sciences, University of Brasilia , Brasilia, Brazil.
authors.forename: A A
authors.initials: AA
authors.lastname: Souza
authors.affiliation: Laboratory of Molecular Biophysics, Institute of Biological Sciences, University of Brasilia , Brasilia, Brazil.
authors.forename: Jarg
authors.initials: J
authors.lastname: Barbosa
authors.affiliation: Laboratory of Molecular Biophysics, Institute of Biological Sciences, University of Brasilia , Brasilia, Brazil.
authors.forename: M M
authors.initials: MM
authors.lastname: Ventura
authors.affiliation: Laboratory of Molecular Biophysics, Institute of Biological Sciences, University of Brasilia , Brasilia, Brazil.
authors.forename: S M
authors.initials: SM
authors.lastname: de Freitas